Startup inhaled drug developer AeroRx Therapeutics and nebulizer maker HCmed Innovations have announced that they will partner on development of a nebulized LABA/LAMA inhalation solution for the treatment of COPD. AeroRx is a spinoff of iPharma Labs, which was acquired by Kindeva Drug Delivery earlier this year. In March 2022, HCmed announced that it was partnering … [Read more...] about HCmed Innovations and AeroRx Therapeutics partner on nebulized LABA/LAMA for COPD
Business
Transpire Bio contracts with Recipharm for development of two more inhaled drugs
After announcing a deal with Recipharm for development of two inhaled drugs (TRB-1 and TRB-2) earlier this year, Transpire Bio says that it has signed an agreement with the CDMO for development of an additional two inhaled products. Under the new agreement, Recipharm will provide development services for Transpire's TRB-3 and TRB-4 inhaled therapeutics for the … [Read more...] about Transpire Bio contracts with Recipharm for development of two more inhaled drugs
Ocugen licenses intranasal COVID-19 vaccine from Washington University in St. Louis
Ocugen announced that it has acquired US, European, and Japanese rights to an intranasal COVID-19 vaccine developed at Washington University in St. Louis. In September 2020, Bharat Biotech announced that it had acquired rights to rights to the Washington University intranasal COVID-19 vaccine outside of the United States, Europe, and Japan, and Bharat recently … [Read more...] about Ocugen licenses intranasal COVID-19 vaccine from Washington University in St. Louis
Qnovia raises $17 million for development of inhaled nicotine replacement therapy
According to Qnovia, which recently changed its name from Respira Technologies, the company has closed a $17 million Series A financing round led by Blue Ledge Capital, with the funds intended to support development of the company's RespiRx inhaled nicotine replacement therapy (NRT). The company said that it intends to submit an IND for the NRT product and anticipates … [Read more...] about Qnovia raises $17 million for development of inhaled nicotine replacement therapy
RS BioTherapeutics raises $3 million for development of RSBT-001 inhaled cannabidiolic acid
RS BioTherapeutics, which recently announced positive results from a proof of concept study of its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) in a mouse model, said that the company has raised $3 million in a Seed II funding round. The company says that it is partnered with Synthonics and Marshall University on development of a nebulized formulation of RSBT-001 … [Read more...] about RS BioTherapeutics raises $3 million for development of RSBT-001 inhaled cannabidiolic acid
Recipharm joins IPAC-RS
CDMO and device maker Recipharm has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as a member, the company announced. Recipharm will be represented on the IPAC-RS Board by Head of Commercial – Advanced Delivery Systems Peter Hirst and Director of Inhalation Sciences and Product Development Lei Mao. According to … [Read more...] about Recipharm joins IPAC-RS
Startup Moat Biotechnology announces funding round, positive interim Phase 1 results for its intranasal COVID-19 vaccine
Startup Moat Biotechnology announced the initiation of a funding round led by Cortado Ventures that aims to raise up to $20 million for continued development of the company's intranasal vaccine against COVID-19. According to the announcement, Tetherex Pharmaceuticals has spun out MoatBio in order to develop single-cycle adenovirus vaccines based on SC-AdVax … [Read more...] about Startup Moat Biotechnology announces funding round, positive interim Phase 1 results for its intranasal COVID-19 vaccine
Akorn settles False Claims Act case involving continued sales of azelastine nasal spray as prescription-only after OTC conversion
The US Department of Justice has announced that Akorn will pay $7.9 million to settle a case related to submission of false claims to Medicare Part D after the company continued to sell three products, including azelastine nasal spray, as prescription drugs after conversion to over-the-counter. The allegations were initially made in a suit brought by a whistleblower … [Read more...] about Akorn settles False Claims Act case involving continued sales of azelastine nasal spray as prescription-only after OTC conversion
RIGImmune to develop intranasal stem-loop RNA therapeutics
Yale University spinout RIGImmune, which has been developing stemloop RNA (SLR) therapeutics, announced that it has acquired biotech Subintro, which has been working on antivirals for RNA virus-caused respiratory infections. The company will now develop intranasal therapeutics "that both activate the natural immune activation and demonstrate antiviral activity," … [Read more...] about RIGImmune to develop intranasal stem-loop RNA therapeutics
ALS Association to fund preclinical study of intranasal foralumab
According to Tiziana Life Sciences, The ALS Association will award a Lawrence & Isabel Barnett Drug Development Program Grant to the Ann Romney Center for Neurologic Diseases at the Brigham and Women’s Hospital (BWH) for a preclinical study of Tiziana's intranasal foralumab anti-CD3 monoclonal antibody. The company said that researchers at BWH will evaluate the … [Read more...] about ALS Association to fund preclinical study of intranasal foralumab